AstraZeneca provides updates at the ESC Congress
At this year’s annual European Society of Cardiology conference (ESC Congress 2024), which took place from 30 August – 2 September, AstraZeneca presented research that spans 38 abstracts, focusing on unmet need in heart failure (HF) and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), and other chronic diseases.
Data highlights from the pharma company included:
- Contemporary Description of Cardiac Manifestations in ATTR Amyloidosis: Results from the Multi-Country OverTTuRe Study
- Study Design of the CARDIO-TTRansform Cardiac Magnetic Resonance Substudy
- Patient Characteristics and Incidence of Cardiac Amyloidosis: An Observational Study in the UK Clinical Setting Using Electronic Health Records
- Chronic Kidney Disease in Patients with Heart Failure in German Primary Care Practices: The InspeCKD Study
Significant results: HFpEF and ATTR-CM
Of those four presentations, particularly noteworthy was AstraZeneca’s presentation highlighting the connection between HF with preserved ejection fraction (HFpEF) and ATTR-CM, a potentially fatal type of amyloidosis affecting ~500,000 people globally, as well as metabolic and kidney interconnections with HF.
HF affects 64 million people globally. With the global economic burden of HF ($346 billion) expected to more than double by 2030, immediate action is required for early detection and intervention to reduce the disease burden and impact on patients, economies and society at large.
AstraZeneca and its partner Ionis are currently running the CARDIO-TTRansform Phase III trial, reportedly the largest, most comprehensive trial in ATTR-CM to date, which is now fully recruited. At ESC Congress 2024, study design details of the CARDIO-TTRansform cardiac magnetic resonance (CMR) sub-analysis were presented representing the largest CMR study conducted in ATTR-CM patients, intended to evaluate the impact of eplontersen on the cardiac amyloid burden.
CARDIO-TTRansform is designed to deliver the most robust data in a broad population of patients, including those on or naïve to stabilisers, that represents the dynamic and evolving ATTR-CM treatment landscape.
Megan Thomas, Multimedia Editor, DDW
